Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer

被引：1
作者：
Cheng, Pin -Nan [1 ]
Yu, Ming -Lung [2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan
[2] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ, Coll Med, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ, Ctr Liquid Biopsy & Cohort Res, Kaohsiung, Taiwan
[5] Natl Sun Yat sen Univ, Sch Med, Kaohsiung, Taiwan
[6] Natl Sun Yat sen Univ, Coll Med, Doctoral Program Clin & Expt Med, Kaohsiung, Taiwan
[7] Natl Sun Yat sen Univ, Ctr Excellence Metab Associated Fatty Liver, Kaohsiung, Taiwan
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2024年 / 30卷 / 02期
关键词：
TDF; TAF; HBV; SDG; 3; Good health and well-being; MORTALITY; THERAPY;
D O I：
10.3350/cmh.2024.0115
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：4
相关论文
共 15 条
  • [1] Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety
    Chan, Henry L. Y.
    Buti, Maria
    Lim, Young-Suk
    Agarwal, Kosh
    Marcellin, Patrick
    Brunetto, Maurizia
    Chuang, Wan-Long
    Janssen, Harry L. A.
    Fung, Scott
    Izumi, Namiki
    Abdurakhmanov, Dzhamal
    Jablkowski, Maciej
    Celen, Mustafa K.
    Ma, Xiaoli
    Caruntu, Florin
    Flaherty, John F.
    Abramov, Frida
    Wang, Hongyuan
    Camus, Gregory
    Osinusi, Anu
    Pan, Calvin Q.
    Shalimar
    Seto, Wai-Kay
    Gane, Edward
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (03) : 486 - 496
  • [2] Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases
    Cheng, Pin-Nan
    Chen, Wen-Jone
    Hou, Charles Jia-Yin
    Lin, Chih-Lin
    Chang, Ming-Ling
    Wang, Chia-Chi
    Chang, Wei-Ting
    Wang, Chao-Yung
    Lin, Chun-Yen
    Hung, Chung-Lieh
    Peng, Cheng-Yuan
    Yu, Ming-Lung
    Chao, Ting-Hsing
    Huang, Jee-Fu
    Huang, Yi-Hsiang
    Chen, Chi-Yi
    Chiang, Chern-En
    Lin, Han-Chieh
    Li, Yi-Heng
    Lin, Tsung-Hsie
    Kao, Jia-Horng
    Wang, Tzung-Dau
    Liu, Ping-Yen
    Wu, Yen-Wen
    Liu, Chun-Jen
    [J]. CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (01) : 16 - 36
  • [3] Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
    Cheng, Pin-Nan
    Feng, I-Cher
    Chen, Jyh-Jou
    Kuo, Hsing-Tao
    Lee, Pei-Lun
    Yu, Ming-Lung
    Chiu, Yen-Cheng
    Chiu, Hung-Chih
    Chien, Shih-Chieh
    Chen, Pei-Jer
    Liu, Chun-Jen
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 230 - 238
  • [4] Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B
    Choi, Hannah S. J.
    Brouwer, Willem P.
    Zanjir, Wayel M. R.
    de Man, Robert A.
    Feld, Jordan J.
    Hansen, Bettina E.
    Janssen, Harry L. A.
    Patel, Keyur
    [J]. HEPATOLOGY, 2020, 71 (02) : 539 - 548
  • [5] Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study
    Giacomelli, Andrea
    Conti, Federico
    Pezzati, Laura
    Oreni, Letizia
    Ridolfo, Anna Lisa
    Morena, Valentina
    Bonazzetti, Cecilia
    Pagani, Gabriele
    Formenti, Tiziana
    Galli, Massimo
    Rusconi, Stefano
    [J]. BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [6] Hajar Rachel, 2016, Heart Views, V17, P78, DOI 10.4103/1995-705X.185130
  • [7] Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
    Hong, Hyeyeon
    Choi, Won-Mook
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Choi, Jonggi
    [J]. CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (01) : 49 - 63
  • [8] Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis
    Jeong, Joonho
    Shin, Jung Woo
    Jung, Seok Won
    Park, Eun Ji
    Park, Neung Hwa
    [J]. CLINICAL AND MOLECULAR HEPATOLOGY, 2022, 28 (02) : 254 - 264
  • [9] The impact of chronic hepatitis B infection on major adverse cardiovascular events and all-cause mortality in patients with diabetes: a nationwide population-based study from Taiwan
    Kuo, Chin-Sung
    Chen, Yung-Tai
    Hsu, Chien-Yi
    Chang, Chun-Chin
    Chou, Ruey-Hsing
    Li, Szu-Yuan
    Kuo, Shu-Chen
    Huang, Po-Hsun
    Chen, Jaw-Wen
    Lin, Shing-Jong
    [J]. BMJ OPEN, 2017, 7 (08):
  • [10] Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients
    Lai, Rui-Min
    Lin, Shan
    Wang, Miao-Miao
    Li, Na
    Zhou, Jia-Hui
    Lin, Xiao-Yu
    Chen, Tian-Bin
    Zhu, Yue-Yong
    Zheng, Qi
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (08) : 964 - 972
12